# Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer

> **NCT04113005** · EARLY_PHASE1 · UNKNOWN · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 10 (estimated)

## Conditions studied

- Castrate Resistance Prostate Cancer

## Interventions

- **DRUG:** Desmopressin

## Key facts

- **NCT ID:** NCT04113005
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-10-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2019-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04113005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04113005, "Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04113005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*